Eos Energy Enterprises Inc vs Revvity Inc — how do they compare? Eos Energy Enterprises Inc trades at $4.19 (market cap $1.54B), while Revvity Inc trades at $115.96 (market cap $12.91B). The key difference: Revvity Inc is far larger — about 8.4× Eos Energy Enterprises Inc's market cap, and Revvity Inc pays a 0.24% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| EOSE | RVTY | |
|---|---|---|
Market Cap | $1.54B | $12.91B |
Sector | Energy | Technology |
52-Week High | $19.19 | $117.75 |
52-Week Low | $3.14 | $82.26 |
Enterprise Value | $1.88B | $15.23B |
Dividend Yield | — | 0.24% |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.38, up 8.15% on the day, amid mixed technical signals and persistent fundamental challenges. The company reported a Q2 2026 loss of $1.20 per share, missing estimates, but revenue growth is accelerating, with 2026 revenue projected at $214 million. Negative profit margins and cash burn remain significant concerns, though analyst sentiment shows a mixed but cautious outlook with a consensus price target of $7.75.
The stock presents a high-risk opportunity driven by revenue growth potential in energy storage, but investors face substantial risks from continued losses, dilution, and competitive pressures. Upside depends on execution improving margins and achieving profitability, while downside risks include further earnings misses and liquidity challenges.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →